0001209191-17-055918.txt : 20171004 0001209191-17-055918.hdr.sgml : 20171004 20171004170100 ACCESSION NUMBER: 0001209191-17-055918 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171002 FILED AS OF DATE: 20171004 DATE AS OF CHANGE: 20171004 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chodakewitz Jeffrey CENTRAL INDEX KEY: 0001610876 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 171122307 MAIL ADDRESS: STREET 1: C/O TETRAPHASE PHARMACEUTICALS, INC. STREET 2: 480 ARSENAL ST., SUITE 101 CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-10-02 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001610876 Chodakewitz Jeffrey C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP GMDA, CMO Common Stock 2017-10-02 4 M 0 3437 73.51 A 117861 D Common Stock 2017-10-02 4 S 0 1394 151.04 D 116467 D Common Stock 2017-10-02 4 S 0 1443 151.82 D 115024 D Common Stock 2017-10-02 4 S 0 600 152.62 D 114424 D Stock Option (Right to Buy) 73.51 2017-10-02 4 M 0 3437 0.00 D 2024-01-01 Common Stock 3437 3438 D Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $151.04 (range $150.37 to $151.36). Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $151.82 (range $151.47 to $152.18). Open market sales reported on this line occurred at a weighted average price of $152.62 (range $152.54 to $152.70). The option vests in 16 quarterly installments from 1/2/2014. /s/ Omar White, Attorney-in-Fact 2017-10-04